Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z Cytotoxic Conjugates at Upcoming AACR Annual

 Aeterna Zentaris to Present Update on its LHRH Receptor-Targeted Disorazol Z
             Cytotoxic Conjugates at Upcoming AACR Annual Meeting

PR Newswire

QUÉBEC CITY, April 3, 2013

QUÉBEC CITY, April 3, 2013 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX:AEZ) (the"Company") today announced that Babette Aicher, PhD, Director
of Preclinical Development, will be making a poster presentation on updated
proof-of-concept results for Disorazol Z cytotoxic conjugates, such as
AEZS-125 and AEZS-138, in human ovarian and endometrial cancer xenograft
models, at the upcoming American Association for Cancer Research ("AACR")
annual meeting, which will be held April 6-10, 2013, in Washington D.C. The
study is funded through a grant from the German Ministry of Education and
Research.

Abstract #5476: "LHRH receptor targeting as mechanism of anti-tumor activity
                for cytotoxic conjugates of Disorazol Z with the LHRH receptor
                agonistic peptide D-Lys6-LHRH", B. Aicher, T. Schuster, L.
                Blumenstein, A. Schubert, C. Gruendker, J.B. Engel, O.
                Ortmann, R. Mueller, E.Guenther, M. Gerlach, M. Teifel.
Session:        Experimental and Molecular Therapeutics 37
Date & Time:    Wednesday, April 10, 2013, from 8:00 a.m. to 12:00 p.m.
                (eastern)
Venue:          Hall A-C Poster Section 36, Walter E. Washington Convention
                Center

About Disorazol Z

Disorazol Z is a novel natural compound, with outstanding cytotoxic activity,
isolated from the myxobacterium Sorangium cellulosum. Disorazol Z, a
macrocyclic polyketide, is produced by a fermentation process providing high
yield and purity. Besides tubulin binding, Disorazol Z has pro-apoptotic
properties and has been shown to arrest cancer cells in G2 stage of the cell
cycle at subnanomolar concentrations. Disorazol Z is an ideal partner for the
formation of cytotoxic conjugates with peptides, proteins, and antibodies to
selectively target cancer cells.

About Disorazol Z cytotoxic conjugates such as AEZS-125 and AEZS-138

AEZS-125 and AEZS-138 are novel cytotoxic conjugates based on the natural
compound Disorazol Z and the luteinizing hormone-releasing hormone ("LHRH")
receptor agonist D-Lys^6-LHRH. The peptide part directs the conjugates
specifically to LHRH receptor expressing tumor cells, and mediates binding and
uptake via endocytosis. Within the cancer cell, the conjugates are cleaved and
Disorazol Z can deploy its potent anti-proliferative activity.

According to the literature, LHRH receptors occur in a number of human tumors,
specifically in about 80% of ovarian and endometrial cancers. They are also
expressed in prostate, urinary bladder and triple-negative breast cancer,
while they are rarely found in normal tissues, except for the pituitary gland
and reproductive organs. The LHRH receptor displays ideal properties for
selective drug targeting.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information, visit
www.aezsinc.com.

SOURCE AETERNA ZENTARIS INC.

Contact:

Investor Relations
Ginette Beaudet Vallières
(418) 652-8525 ext. 265
gvallieres@aezsinc.com

Media Relations
Paul Burroughs
(418) 652-8525 ext. 406
pburroughs@aezsinc.com